EXELIXIS AGAIN They said: Sell EXEL, as no partner is interested in the firm’s FDA approved …

GILEAD SCIENCES The people who cause the selloff of Gilead’s (GILD) stock because it missed 5 …

Biotech NEWS   AGENUS Agenus’ First Checkpoint Inhibitor to reach Clinical Trial The first patient has …

The AACR 2016 meeting presentations differed substantially from previous meetings. The  2016 meeting has brought near …

Meaningful Presentations at the Annual Meeting of the American Association for Cancer Research (AACR) NEKTAR THERAPEUTICS …

Pursuing its goal in treating hepatitis, Gilead Sciences (GILD) is at the finish line of clinical trials on …

Regeneron and Intellia to Discover and Develop CRISPR/Cas Therapeutics Moving forward is Regeneron Pharmaceuticals’ (REGN) strategy based on strong …

Another day, another badly needed treatment for a dangerous disease is on its way to be …

Pfizer (PF) terminated its acquisition agreement with Allergan Plc (AGN) The new set of rules released by …

Prohost Letter #394 Part 2 PART 2 - Part 1 of the Prohost letter issue #394 posted …